-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On the evening of June 22, the official website of the National Medical Products Administration (NMPA) of China announced that BeiGene's new anti-PD-1 antibody drug tislelizumab has launched two new indications (sDNA) for lung cancer and liver cancer.
According to a press release issued by BeiGene, the indications for these two sDNAs are: combined chemotherapy for the treatment of patients with first-line advanced non-squamous non-small cell lung cancer (NSCLC), and treatment of unresectable livers that have received previous treatment.
Screenshot source: NMPA official website
The approval of the NMPA makes tislelizumab a first-line immunotherapy for patients with advanced squamous and non-squamous non-small cell lung cancer